JAV - I rarely see a bio-tech give a CC to update the clinical progress and then the stock price respond positively. I think shorts & traders get a better idea when any clinical milestones will be reached and use it to their advantage. Maybe investors were disappointed with the nasal Ketamine timelines or thought that Dyloject could be delayed since their waiting the manufacturing re-inspection. Who knows, painful day is all I can say.
the only thing I can think of is the (slightly) slipping timeline on dyloject approval..6 months ago it was H1 2007, more recently summer 2007, and now a reinspection to presumably settle lingering gmp issues
of course this is an overreaction to the above, and I agree makes for a good buying opportunity
News 
Market Data 
Discover 
AI
